|Mr. Andrew R. Robbins M.B.A.||Pres, CEO & Director||961.32k||N/A||1976|
|Dr. John Edward Robinson Ph.D.||Chief Scientific Officer||560.22k||N/A||N/A|
|Dr. Jessica Sachs M.D.||Chief Medical Officer||595.24k||N/A||1975|
|Mr. John L. Green C.A., CPA||CFO & Principal Accounting Officer||N/A||N/A||1980|
|Mr. Brad Barnett||Chief Technology Officer||N/A||N/A||N/A|
|Mr. Evan D. Kearns J.D.||Chief Legal Officer & Corp. Sec.||N/A||N/A||1980|
|Ms. Erin Schellhammer||Chief People Officer||N/A||N/A||N/A|
|Ms. Sara Saltzman||Sr. VP of Regulatory Affairs||N/A||N/A||N/A|
|Mr. Dana R. Martin Pharm.D.||Sr. VP of Medical Affairs & Chief Patient Officer||N/A||N/A||N/A|
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Cogent Biosciences, Inc.’s ISS Governance QualityScore as of July 31, 2022 is 8. The pillar scores are Audit: 9; Board: 6; Shareholder Rights: 8; Compensation: 9.